Preliminary study of DA or HA regimen chemotherapy for the treatment of refractory and relapsed paroxysmal nocturnal hemoglobinuria.
- Author:
Yan-ran CAO
1
;
Zong-hong SHAO
;
Hai-rong JIA
;
Juan SUN
;
Hong LIU
;
Yu-hong WU
;
Tie-jun QIN
;
Jun SHI
;
Jie BAI
;
Guang-sheng HE
;
Rong FU
;
Ming-feng ZHAO
;
Hai-feng TU
;
Zhen-zhu CUI
;
Tian-ying YANG
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Cytarabine; administration & dosage; Daunorubicin; administration & dosage; Drug Therapy, Combination; Female; Glycosylphosphatidylinositols; analysis; Harringtonines; Hemoglobinuria, Paroxysmal; drug therapy; Humans; Male
- From: Chinese Journal of Hematology 2004;25(4):202-204
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo observe the efficacy and side effect of DA/HA regimen chemotherapy for the treatment of refractory and relapsed paroxysmal nocturnal hemoglobinuria (PNH).
METHODSEight patients with refractory and relapsed PNH were treated with DA/HA regimen chemotherapy. Three patients were treated with DA (DNR 40 mg/d, i.v.drip, the first and the second day; 20 mg/d, i.v.drip, the third day; Ara-C 100 mg/d, i.v.drip, for 5 days) and 5 patients with HA (HHT 2 - 3 mg/d, i.v.drip, for 5 days; Ara-C 100 mg/d, i.v.drip, for 5 days).
RESULTSAll the 8 patients responded well: the PNH clone was diminished in five patients. Hemolysis was remitted in 6 cases. Five patients showed improvement in hematological parameters. The dosage of corticosteroid was decreased in all of them. No serious side effect was revealed.
CONCLUSIONDA/HA regimen chemotherapy was safe and effective for refractory and relapsed PNH patients.
